Research In Brief
This article was originally published in The Gray Sheet
Breast cancer imaging: Naviscan PEM positron emission mammography scanner was more effective in differentiating between benign and cancerous lesions than MRI in women newly diagnosed with breast cancer, according to results of an NIH-sponsored, prospective, multi-year, 388-patient study released Oct. 29. PEM scans demonstrated 80% specificity, correctly distinguishing 151 of 189 benign lesions, compared to 66% specificity for MRI. In addition, combining PEM and MRI significantly increased a physician's ability to detect potentially cancerous lesions versus MRI alone. San Diego-based Naviscan's device is a high-resolution positron emission tomography system that can show the location as well as the metabolic phase of a lesion to help determine malignancy. The system launched in 2007 and is available at 35 sites worldwide
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.